Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

tooz company pty ltd - chlorine present as sodium hypochlorite - liquid - chlorine present as sodium hypochlorite mineral-chlorine active 130.0 g/l - algicide - swimming pool - algae | bacteria

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

tooz company pty ltd - chlorine present as trichloroisocyanuric acid - pool chlorine - swimming pool - algae | bacteria

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

tooz company pty ltd - chlorine present as sodium dichloroisocyanurate - pool algicide - swimming pool - algae | bacteria

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

tooz company pty ltd - chlorine present as calcium hypochlorite - pool algicide - swimming pool - algae | bacteria

Kanada - Kiingereza - Health Canada

hoffmann-la roche limited - pertuzumab - solution - 420mg - pertuzumab 420mg - antineoplastic agents

Kanada - Kiingereza - Health Canada

hoffmann-la roche limited - pertuzumab; trastuzumab - solution - 420mg; 440mg - pertuzumab 420mg; trastuzumab 440mg - antineoplastic agents

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hyprolose; hydrogenated vegetable oil; mannitol; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide red; macrogol 400; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia; strong ammonia solution; ethanol - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - clopidogrel besilate, quantity: 111.86 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: mannitol; microcrystalline cellulose; colloidal anhydrous silica; stearic acid; hypromellose; titanium dioxide; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.,acute coronary syndrome,clopidogrel is indicated in combination with aspirin for patients with:,-unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent).,-st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - clopidogrel hydrogen sulfate, quantity: 97.875 mg (equivalent: clopidogrel, qty 75 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; colloidal anhydrous silica; hyprolose; lactose monohydrate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; iron oxide red - for prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ,acute coronary syndrome: clopidogrel tablets is indicated in combination with aspirin for patients with: ,- unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). clopidogrel tablets is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularization (surgical or pci, with or without stent); ,- st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.